Test Price
2,800 AED✅ Home Collection Available
CBL Gene Genetic Test for Noonan Syndrome-like Disorder with or without Juvenile Myelomonocytic Leukemia in UAE | 2800 AED | DHA-Compliant NGS Analysis
Executive Summary & Core Metrics
-
✓
99.9% Diagnostic Sensitivity – ISO‑accredited next‑generation sequencing (NGS) covering the entire coding region and splice sites of the CBL gene.
-
✓
VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection – available daily from 8 AM to 11 PM across all UAE emirates, including Dubai, Abu Dhabi, and Sharjah.
-
✓
Post‑Test Clinical Guidance – telephonic consultation with a DHA‑licensed genetic counsellor to interpret results and plan follow‑up care.
-
✓
Direct Billing Verification – WhatsApp +971 54 548 8731 for insurance pre‑approval and direct billing inquiries.
Test Overview & Methodology
This next‑generation sequencing (NGS) test interrogates the entire coding region and intron‑exon boundaries of the CBL gene to identify germline mutations associated with Noonan syndrome‑like disorder and predisposition to juvenile myelomonocytic leukemia (JMML). The analysis is performed in an ISO 9001:2015‑certified laboratory using validated bioinformatics pipelines, and all variant interpretations follow ClinGen and DHA guidelines.
| Feature | Our CBL NGS Test | Conventional Panel |
|---|---|---|
| Coverage | Full gene coding region + splice sites | Selected exons only |
| Method | NGS with validated bioinformatics (ISO 9001:2015) | Sanger sequencing / limited NGS |
| Turnaround Time | 3–4 weeks | 4–6 weeks (often fragmented) |
| Clinical Report | DHA‑compliant, ClinGen‑curated variant interpretation | Limited interpretation |
Physician Insight & Safety Protocols
“As a DHA‑licensed Consultant Medical Genetics, I emphasize that this NGS test provides powerful risk stratification for Noonan syndrome‑like disorder and JMML predisposition. However, a positive result must be interpreted within the context of a full clinical evaluation, family history, and multidisciplinary follow‑up. Early detection combined with a coordinated care plan can significantly improve long‑term outcomes for affected children.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics | DHA Registration ID: 9294403
Medication Advisory
Medication Advisory
Do not alter, pause, or discontinue any prescribed medication without direct instruction from your supervising physician. Genetic test results are intended to guide long‑term surveillance and management decisions, not to replace acute clinical judgment. Always consult your healthcare provider before making any changes based on test findings.
Exclusion Criteria & Red Flags
Exclusion Criteria
- Inadequate DNA yield from provided sample (requires recollection)
- Recent allogeneic bone marrow transplant (donor DNA interference)
- Known somatic mosaicism best assessed via tissue biopsy
- Severe hemolysis or clotting compromising sample integrity
Emergency Red Flags (Seek Immediate Care)
- Unexplained fever >38.5°C, petechiae, or unusual bruising
- Rapidly enlarging spleen or liver, or respiratory distress
- Severe pallor, persistent bleeding, or lethargy
If any red flag appears during the waiting period, contact your pediatric hematologist or emergency department immediately. This test does not serve as emergency triage.
Patient FAQ & Clinical Guidance
1. What is the CBL gene NGS test and why is it done?
This test sequences the entire CBL gene to detect germline mutations causing Noonan syndrome‑like features and increased risk of juvenile myelomonocytic leukemia. It guides early surveillance and tailored management for affected children and at‑risk family members.
2. How long until I receive the results?
Your comprehensive CBL gene report is delivered within 3 to 4 weeks from the day the lab receives your sample. We provide SMS and WhatsApp notifications along with secure online portal access for your report.
3. Can a mobile phlebotomist collect the sample at my home in Dubai or Abu Dhabi?
Yes, our ISO‑certified home collection service covers all UAE emirates, including Dubai, Abu Dhabi, and Sharjah, from 8 AM to 11 PM. A trained paediatric phlebotomist arrives with a full cold‑chain kit and collects a small blood sample or a single drop on an FTA card if preferred.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under DHA Facility License Number 1143 and strictly complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All genetic data is encrypted, stored securely, and accessible only to authorised medical personnel for clinical interpretation. Patient consent is obtained in full accordance with Federal Decree‑Law No. 4 of 2016 on Medical Liability.
Clinical & Logistical Metadata
| Test Name | CBL Gene Next‑Generation Sequencing (NGS) – Noonan Syndrome‑like Disorder / JMML Predisposition |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (3–5 mL in EDTA tube) or FTA card dried blood spot |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full gene coding region + splice sites, ISO 9001:2015 certified |
| ICD‑10‑CM Code | Q87.19 |
| LOINC Code | 89539-1 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE – DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians